Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

reported outcomes measuring symptoms, pain, activities of daily living, sport and recreational activities and quality of life associated with the operated knee showed a sustained benefit through postoperative Day 90.

In the first quarter of 2011, Omeros announced that OMS103HP failed to meet pre-specified efficacy endpoints in a Phase 3 clinical program in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. Omeros is unable to draw any conclusions about OMS103HP's effect in the Phase 3 ACL program due to confounding factors, and the Company has no plans to conduct additional ACL reconstruction trials at this time. The primary endpoint for Omeros' meniscectomy Phase 3 trials is different than that used in its ACL program. Accordingly, Omeros believes that the results of its ACL program do not affect the viability of its meniscectomy program.

Omeros' OMS302 Program

OMS302 is Omeros' PharmacoSurgery™ product candidate being developed for use during ophthalmological procedures including cataract and other lens replacement surgery. OMS302 is a proprietary combination of an anti-inflammatory API and an API that causes mydriasis (pupil dilation), each with well-known safety and pharmacologic profiles. FDA-approved drugs containing each of these APIs have been used in ophthalmological clinical practice for more than 15 years, and both APIs are contained in generic, FDA-approved drugs.

In a Phase 2b clinical trial that evaluated OMS302 in patients undergoing cataract surgery, OMS302 demonstrated clinically meaningful and statistically significant benefits in both prespecified co-primary endpoints – maintenance of intraoperative mydriasis and reduction of pain in the early postoperative period. OMS302 also reduced the frequency of complaints of moderate and severe pain.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to disc
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
(Date:10/17/2014)... Investor-Edge has initiated coverage on the following ... NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), XOMA ... (NASDAQ: MNTA ), and Catalyst Pharmaceutical Partners ... can be accessed at: http://investor-edge.com/register . ... on a mixed note as the Dow Jones Industrial ...
(Date:10/17/2014)... SM , the nation,s leader in medication monitoring solutions, ... M.D., as Chief Medical Officer. In this role, Smith ... healthcare providers, patients and managed care plans.   ... of healthcare companies that have provided him with experiences ... sides of Ameritox,s business. He most recently served as ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... , PITTSBURGH , May 4 Mylan Inc. (Nasdaq: ... final approval from the U.S. Food and Drug Administration (FDA) for its ... 150 mg, the generic version of GlaxoSmithKline,s smoking cessation aid, Zyban®.   ... Bupropion HCl ER Tablets ...
... , May 3 Avantis ... catheter-mounted digital imaging devices, today announced five new studies ... colonoscopy procedures increases detection of adenomas and polyps.  The ... experience, were able to detect adenomas of all sizes ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Zyban(R) 2Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 2Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 3Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 4Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 5Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 6
(Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... Even when surgical tumor removal is combined with a heavy ... cancer will not return. Now researchers at Tel Aviv University ... and an immunity to the cancer,s return with ... "tumor ablation" a process through which the tumor is destroyed ...
... study into the ways lungs grow and develop has challenged ... the age of three. The researchers, led by a ... for the first time based on research evidence that new ... contradicts information in most medical textbooks that explain that the ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Dec. 5 ... for his overall health than his body weight, a novel finding ... online Dec. 5 in the journal Circulation finds that ... live longer, regardless of whether your body weight has stayed the ...
... MONDAY, Dec. 5 (HealthDay News) -- Eating fish rich ... significantly lower a young woman,s risk of developing heart ... of childbearing age who never ate fish had 50 percent ... a 90 percent higher risk than women who ate fish ...
... PARK, Md. -- Social determinants, including the lack of paid ... influenza A (H1N1) virus among Hispanics in the U.S. during ... Sandra Crouse Quinn, professor of family science and senior associate ... University of Maryland School of Public Health. The findings are ...
... Dec. 5 (HealthDay News) -- Policies that dictate minimum requirements ... increased levels of physical activity among children, a new ... in school, which makes schools important locations for combating overweight ... Illinois at Chicago noted in the report, published online Dec. ...
Cached Medicine News:Health News:Blasting cancer from the inside out 2Health News:Blasting cancer from the inside out 3Health News:University of Leicester study fundamentally alters our understanding of lung growth 2Health News:Fitness May Lower Death Risk Even Without Weight Loss 2Health News:Fitness May Lower Death Risk Even Without Weight Loss 3Health News:Fish May Cut Threat of Heart Disease in Young Women 2Health News:Fish May Cut Threat of Heart Disease in Young Women 3Health News:Maryland study finds that US Hispanics were at greater risk for H1N1 flu during 2009 pandemic 2Health News:U.S. School Kids Often Miss Out on Recess, Study Finds 2
Fine .12mm Tip With 5mm Platform; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Curved 30mm shaft (in stainless steel); rubber coated for safer use; includes 1.5 meter cable and connectors....
0.3mm tips; 9.5mm from tips to cross action; in Titanium....
Medicine Products: